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Abstract
Background: The primary aim was to test the hypothesis that deriving pre-treatment 3D magnetic resonance
tumour volume (mrTV) quantification improves performance characteristics for the prediction of loco-regional
failure compared with standard maximal tumour diameter (1D) assessment in patients with squamous cell
carcinoma of the anus undergoing chemoradiotherapy.
Methods: We performed an early evaluation case-control study at two UK centres (2007–2014) in 39 patients with
loco-regional failure (cases), and 41 patients disease-free at 3 years (controls). mrTV was determined using the
summation of areas method (Volsum). Reproducibility was assessed using intraclass concordance correlation (ICC)
and Bland-Altman limits of agreements. We derived receiver operating curves using logistic regression models and
expressed accuracy as area under the curve (ROCAUC).
Results: The median time per patient for Volsum quantification was 7.00 (inter-quartile range, IQR: 0.57–12.48) minutes.
Intra and inter-observer reproducibilities were generally good (ICCs from 0.79 to 0.89) but with wide limits of agreement
(intra-observer: − 28 to 31%; inter-observer: − 28 to 46%). Median mrTVs were greater for cases (32.6 IQR: 21.5–53.1 cm3)
than controls (9.9 IQR: 5.7–18.1 cm3, p < 0.0001). The ROCAUC for mrT-size predicting loco-regional failure was 0.74 (95% CI:
0.63–0.85) improving to 0.82 (95% CI: 0.72–0.92) when replaced with mrTV (test for ROC differences, p = 0.024).
Conclusion: Preliminary results suggest that the replacement of mrTV for mrT-size improves prediction of loco-regional
failure after chemoradiotherapy for squamous cell carcinoma of the anus. However, mrTV calculation is time consuming
and variation in its reproducibility are drawbacks with the current technology.
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Background
Chemo-radiotherapy (CRT) is the primary treatment for
patients with squamous cell carcinoma of the anus
(SCCA) [1]. The key aim of treatment is to achieve loco-
regional control whilst maintaining sphincter preservation.
However, up to a quarter of those treated report loco-
regional failure (LRF) within 3 years [2]. These patients
may be offered a second attempt of cure with salvage sur-
gery, but this is a radical operation associated with signifi-
cant morbidity and poor long-term outcomes [3].
Until recently, CRT for SCCA adopted a broad “one size
fits all” strategy, typically comprising 5-fluorouracil and
mitomycin concurrent with 50 to 55 Gy radiotherapy, des-
pite a wide spectrum of the loco-regional disease stages at
presentation. Stratified approaches are now being evalu-
ated, as exemplified by the UK PLATO (PersonaLisingrA-
dioTherapydOse in anal cancer, ISRCTN88455282) trial
[4], a single protocol ‘platform’ comprising the ACT3, 4
and 5 trials with the aim of personalising radiotherapy
dose across the disease spectrum. Presently, pre-treatment
MR assessment of T-size (mrT-size), together with nodal
status, are the key determinant of treatment stratification
but this strategy has imperfections. For example, there is
variation in maximum tumour dimensions determined
using T2 weighting imaging [5]. One-dimensional tumour
diameter may not adequately represent tumour biology
that tends to be infiltrative in nature and irregularly
shaped. Furthermore, based on using 7th edition AJCC
staging (where the cut-off from T2 to T3 is 5 cm), Gunder-
son et al. [6] illustrated that there is a considerable ‘jump-
up’ in 3-year LRF rates between T2N0 (10%) and T3N0
(22%), suggesting that T-size alone may not optimally cap-
ture the heterogeneity radio-resistance and risk of LRF.
An alternative imaging approach to pre-treatment sta-
ging is magnetic resonance quantification of tumour vol-
ume (mrTV). This has been explored in other tumour
sites, such as in head and neck [7–10] and lung cancer
[11–14]. However, methods and results have been incon-
sistent. Some studies use 3D quantification techniques
while other have used semi-automated estimates of ellips-
oid volume derived from 1D tumour dimensions. It is un-
clear whether this latter approach is a valid estimate.
The primary aim was to test the hypothesis that deriving
pre-treatment 3D mrTV quantification improves perform-
ance characteristics for the prediction of LRF compared
with standard maximal tumour diameter (1D) assessment
in patients with SCCA undergoing CRT. We chose to
quantify 3D mrTV using a summation of areas method, as
conceptually, this better captures the complex 3-
dimensional nature of an anal tumour compared with esti-
mation methods derived from 1D tumour dimensions. But
in turn, this method may be labour intensive and there may
be considerable variation in reproducibility. Thus, second-
ary aims were to evaluate whether 3D mrTV quantification
directly measured on scans by the summation of area
method is reproducible; and whether volume estimation
derived from less labour intensive 1D tumour dimensions
is a valid estimation of tumour volume.
Methods
In accordance with the CRUK/EORTC imaging biomarker
consensus statement, this was a two-centre Domain 2
validation study evaluating performance characteris-
tics, reproducibility and whether the biomarker is ‘fit
for purpose’ [15].
Patients and treatment
We performed a case-control study at two UK centres, the
Christie NHS Foundation Trust, Manchester, and Leeds
Teaching Hospitals Trust, Leeds (LTHT). Patients were in-
cluded if they had histologically confirmed SCCA; T1 to
T4 disease (AJCC 7th edition) [16]; and had received CRT
with curative intent for non-metastatic disease. For the
control group, patients were free of LRF for at least 3 years
follow-up. Patients with histologies other than SCC were
excluded, as were patients where T-stage was undetermin-
able (Tx disease,) as mrTV and mrT-size parameters could
not be quantified.
All patients were treated between 2007 and 2014 prior to
the introduction of IMRT (Intensity Modulated Radiother-
apy). The treatment protocol followed that used in the
ACT II trial [17] – namely, radiotherapy of 50·4 Gy was de-
livered over 5·5 weeks with a two phase technique, without
a mandatory break. Phase 1 included 30·6Gy in 17 daily
fractions with non-conformal rectangular parallel-opposed
fields. Phase 2 required conformal planning and delivered
19·8Gy in 11 daily fractions over 15 days to the primary
tumour with a 3 cm margin and any involved lymph nodes.
Chemotherapy regimens were administered concurrently
with radiotherapy as either: mitomycin-C (MMC) 12mg/
m2 on day 1, and continuous infusion of 5-fluorouracil (5-
FU) 1000mg/m2 on days 1–4 and days 29–32.
Selection for case-control study
From the retrospective two-centre clinical databases, all
40 patients with LRF from 2007 to 2014 undergoing CRT
and with measureable anal tumours were selected as cases
(one outlier volume later excluded). Forty-one patients
without LRF at 3 years were controls. Control selection
was at random from those patients in the databases with
available MR images satisfying criteria listed next.
Tumour volume quantification
All tumour quantification used routinely collected pre-
treatment MR imaging, performed on a 1.5 Telsa MR
employing optimal pelvic phase-array body coil (acquisition
protocols are detailed in the supplementary material, Table
S1). For inclusion, scans had to meet the following criteria:
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(i) include a small field of view high resolution T2-weighted
(T2W) sequence in the axial plane as minimum, with a slice
thickness ≤ 4mm; (ii) field of view extending above and
below the tumour in two orthogonal planes to allow
complete tumour assessment including TV quantification
and assessment of T-size; and (iii) where the tumour re-
quired more than one series to assess the whole tumour,
then these series had to overlap sufficiently such that the
entire tumour was imaged and could be quantifiable.
To determine mrT-size, three primary orthogonal mea-
surements of the maximal diameters were taken in the
anterior-posterior (AP), left-right (LR) and cranio-caudal
(CC) planes along the axis of the tumour measured on the
high resolution T2W images. The AP and LR diameters
were recorded on the axial plane at the point of maximal
dimension. The longest diameter was noted and the next
dimension was taken at an axis perpendicular to the
above. CC dimension was measured in either the coronal
or sagittal plane. The largest of these three diameters was
considered to be the tumour size (cm). Assessors (RK and
BC) were blind to LRF status.
mrTV measurements were performed using World-
Match (in-house written software from MvH [18]) that
allowed simultaneous contouring on several sequences
of different planes. Pre-treatment MR images were
imported in anonymised DICOM format and the pri-
mary tumour was manually contoured. Delineations
were checked and adjusted accordingly using coronal
and sagittal planes. All contiguous areas of tumour were
contoured together including nodal masses that had coa-
lesced with the tumour or contiguous areas of extra-
mural vascular invasion (EMVI). This was required to
account for difficulties in defining a plane between the
entities and to allow consistency of approach. Separate
or discrete nodal volumes were not included. The asses-
sor (HS) was blind to LRF status.
For the main analysis, mrTV was derived by using a
summation of areas method (Volsum), which sums-up
the area contoured on serial image slices while taking
into account the distance between the slices; i.e. the slice
thickness of the scans (Fig. 1a & b). The time taken to
contour the TV on MR images, was recorded for the
first 22 patients (‘training’) and compared with the
remaining patients.
Intra-and inter-observer variability
Intra- and inter-observer variability of mrTV quantification
was assessed in ten (randomly selected) patients and com-
pared using intra-class concordance correlations (ICC)
with scores < 0.5 representing poor; 0.5 to < 0.75 moderate;
0.75 to < 0.9 good; and ≥ 0.9 excellent agreement [19]. 95%
confidence intervals were derived from z-transformations.
Bland-Altman plots were employed to further assess agree-
ment [20]. We standardised all plots so that y-axis (mean
difference between measure modalities) ranges were
equivalent to those of the x-axis (mean value from both
measure modalities). We then examined each plot for: (i)
mean values closeness to zero; (ii) levels of agreement; and
(iii) that the pattern across the range of means was propor-
tionate i.e. evaluating for trends across the range. For levels
of agreement, we expressed as percentage of the x-axis
range of values and reported as these as ‘wide’ if the limits
fell outside +/− 10% of the average mean difference.
Ellipsoid and elliptical cylinder volume estimation
We tested whether volume estimation derived from 1D
tumour dimensions is a valid estimate of TV, using ellips-
oid and elliptical cylinder equations and measured 1D
diameters (Fig. 1c & d), where d1, d2 and d3 are the
maximal diameters of the primary tumour measured in
the AP, LR and CC planes. The ellipsoid equation was: 43
π  d12  d22  d32 ; the elliptical cylinder equation was:
(π × d1 × d2 × d3)/4. These were assessed for reproducibil-
ity as above. We also evaluated for accuracies compared
with Volsum using the ROCAUC method (we expected el-
lipsoid and elliptical to be equivalent as they are derived
from the same parameters).
Statistical analysis
Stata software, version 14 (Stata Corp., Tx, USA) was
used for all statistical analyses. Continuous data were
summarised as medians with inter-quartile ranges (IQR)
and categorical data were presented as proportions.
Comparisons were by Chi-square and Fisher’s Exact tests
and non-parametric Mann-Whitney U tests, respectively.
Assessment of the discriminatory potential of the differ-
ent tumour quantifications was tested with receiver oper-
ator characteristic curves (ROCs) and estimation of
accuracy using the AUC and compared against each other
using the method of DeLong et al. [21]. Multivariable
models used logistic regression, and derived ROCAUC using
post-estimation commands.
In our power calculation, we posited that 10% would
be a meaningful clinical difference for areas under the
curve ROCAUC. We added 3% as case-control studies
tend to overestimate performance characteristics [22].
Thus, we concluded that 42 cases of LRF and 42 con-
trols of non-LRF patients would be required to reach
ROCAUC difference of 13% at α < 0.001.
We utilised other indicators of performance characteris-
tics, using the methods described by Pencina et al. [23]
which derives two characteristics – the Integrated Discrim-
inatory Improvement (IDI), an index of improvements in
sensitivity relative to specificity, and Net Reclassification
Improvement (NRI), an index of net change in events ver-
sus non-events detected, which in turn focuses on medical
decision making.
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Results
Patient characteristics
Eighty-one patients were initially included in the study.
One case with a tumour volume of 652 cm3 was excluded
as an extreme outlier, leaving 80 patients as characterised
in Table 1. Sixty-one patients were treated at The Christie
and 19 at LTHT. The cases and controls were well-
balanced for age and gender. As expected, the LRF group
had more patients presenting with T3/4 disease compared
with the non-LRF group and more patients presenting
with node positivity. There were no differences noted in
these baseline variables between the patients from The
Christie and LTHT (Table S2).
Volume quantification
mrTV measurements took a median of 7 min, but with wide
variation from less than 1 min to over an hour. Contours
performed in the 22 preliminary patients took longer than
subsequent determinations [median: 10.5 (IQR: 7.2–14.3)
minutes versus 5.6 (IQR: 4.3–12.2) minutes, p = 0.018].
The median volume in all 80 patients determined by
summation of areas was 20.1 (IQR: 9.1–39.0) cm3. The
median mrTV increased with mrT-stage as follows: T1,
5.7 cm3; T2, 9.1 (IQR: 4.6–16.7) cm3; T3, 38.4 (IQR:
21.6–50.2) cm3; T4, 34.5 (IQR: 18.1–66.5) cm3, p < 0.001
(Figure S1).
Reproducibility
Reproducibility was generally good. Intra-observer ICC
scores were 0.89 (95% CI: 0.75 to 1.00); inter-observer
ICC scores were 0.79 (95% CI: 0.55 to 1.00). Agreement
was further explored with Bland-Altman plots, which re-
vealed wide limits of agreement from − 7.93 cm3 (− 28%)
to 8.47 cm3 (31%) for intra-observer variability and −
Fig. 1 Method of quantification of tumour volume: a pelvic axial section of MR images depicting an anal canal tumour contoured in blue
(arrows); b sequential contours rendered to create 3D representation of the tumour, demonstrating its irregular and complex shape; and c
estimation of volume using orthogonal tumour size measurements under the assumption that the tumour volume approximates an ellipsoid. d
estimation of volume using orthogonal tumour size measurements under the assumption that the tumour volume approximates an elliptical
cylinder. Figures (a) and (b) were created using World-Match (inhouse written software). Figures (c) and (d) were created using Microsoft
Office Powerpoint
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7.65 cm3 (− 28%) to 12.59 cm3 (46%) for inter-observer
variability (Fig. 2).
Tumour size versus volume
Median mrT-size was larger in cases compared with con-
trols [5.2 (IQR: 4.3–6.2) cm versus 3.6 (IQR: 2.9–5.2) cm,
p = 0.0004]. Similarly, mrTV determined by summation of
areas was greater in cases compared with controls [32.6
(IQR: 21.5–53.1) cm3 versus 9.9 (IQR: 5.7–18.1) cm3, p =
0.0001] (Fig. 3a).
The ROCAUC for mrT-size predicting LRF was 0.74
(95% CI: 0.63–0.85).This improved to 0.82 (95% CI:
0.72–0.92) when mrTV replaced mrT-size (p = 0.024)
(Fig. 3b). As nodal status is a predictor for LRF [2], we
adjusted for this in two separate multivariable logistic
regression models for mrT and mrTV. The ROCAUC
did not materially change (Table 2).
Ellipsoid and elliptical cylinder estimates
The median volumes estimated from the ellipsoid equa-
tion was 20.6 (IQR: 8.6–44.7) cm3. That for volume esti-
mated from elliptical cylinder equation was higher at 30.8
(IQR: 13.0–67.0) cm3. Agreement was excellent between
Volsum and volume determined by the ellipsoid eq. [ICC
scores =0.91 (95% CI: 0.86 to 0.94)] and good between
Volsum and volume determined by the elliptical cylinder
eq. [ICC scores =0.73 (95% CI: 0.66 to 0.80)]. From, the
Bland-Altman plots, the limits of agreement for Volsum
and volume determined by the ellipsoid equation were
from − 20.4 (− 16%) to 20.1 (17%). For Volsum versus vol-
ume determined by the elliptical cylinder, there was a dis-
proportionate trend with increasing volume (Figure S2).
The ROCAUC for mrTV determined by the ellipsoid
volume estimate was 0.79 (95% CI: 0.68 to 0.89); that for
the elliptical cylinder volume estimate was identical
(Table S3).
Fig. 2 Bland-Altman plots demonstrating intra- and inter-observer (modest) agreement of tumour volume quantification in 10 patients: a average
mean difference of − 0.27 cm3 and limits of agreement from − 7.93 cm3 (− 28%) to 8.47 cm3 (31%) for intra-observer variability; and b average
mean difference − 2.5 cm3 and limits of agreement − 7.65 cm3 (− 28%) to 12.59 cm3 (46%) for inter-observer variability. Figures were created using
Stata software, version 14









Men (%) 14 (34) 16 (41) 0.525a
Women (%) 27 (66) 23 (59)
Median age (IQR), years 60 (53–69) 57 (50–69) 0.563b
mrT-stage (%) 0.018c
T1 1 (2) 0
T2 24 (59) 11 (28)
T3 9 (22) 16 (41)
T4 7 (17) 12 (31)
mr Nodal status
LN− (%) 26 (63) 14 (36) 0.014a
LN+ (%) 15 (37) 25 (64)
LRF Locoregional Failure, non-LRF Without evidence of locoregional failure
after 3-years follow-up, IQR Interquartile Range, LN+ Nodal Involvement; aChi-
square test; bMann-Whitney U Test; cFisher’s Exact Test
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IDI and NRI
For mrTV (measured as Volsum) versus mrT-size, the
IDI was 9.6% (standard error, se: 3.0%), which was statis-
tically different (p = 0.0015). By contrast, the NRI was
potentially large at 34% (se: 22%), but not statistically
significant (p = 0.123).
Discussion
Summary of Main findings
mrTV quantification determined by summation of areas
may improve accuracy to predict for loco-regional failure
when replacing mrT-size. However, this method is time
consuming and variation in reproducibility are drawbacks
Fig. 3 a Dotplots demonstrating the association of tumour volume and T-size with loco-regional failure (LRF) with the patient with the
large volume outlier removed from both analyses: The horizontal black lines represent the median tumour quantification values; the
dashed black lines represent the limits of the interquartile range. The y-axis has been standardised so that the medians in the controls
are aligned (b): Receiver Operator Characteristic curves comparing the discriminatory performance of measured tumour volume and mrT-
size. *AUCs compared by the method of DeLong et al. Figures were created using Stata software, version 14
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with current technology. The use of tumour volume esti-
mates that utilise routinely obtained 1D tumour diameter
measurements (ellipsoid and elliptical cylinder equations)
had imperfect levels of agreement with volume deter-
mined by summation of areas but it is unknown whether
this influences performance characteristics defined by
AUC on ROC analyses.
Context of other literature
To our knowledge, this is the first study to evaluate the
performance characteristics of mrTV and LRF in SCCA.
Many studies [24–29] in patients with SCCA have re-
ported on TNM-related parameters as treatment predic-
tors. Of the six published trials in this field, three [30–32]
reported tumour predictive information, using either
AJCC T-stage or a single one-dimension tumour size cut-
off. In contrast, tumour biology occurs at a 3D level, with
the chance of cure being dependent on factors such as in-
creasing number of tumour clonogens that require sterilis-
ing and the extent of tumour hypoxia, both of which
increase with the bulk of the tumour. Thus, tumour vol-
ume seems a ‘closer to real-life’ model for tumour biology.
MR imaging is the current standard of care for the pre-
treatment staging of SCCA [33], providing high-resolution
imaging. It is tempting to speculate that extension of this
imaging platform to tumour volume quantification could
improve treatment prediction. MR imaging additionally
allows analysis of tumour heterogeneity, another param-
eter that may be a better representation of tumour biology
and offer complementary information to current staging
parameters. One study of forty patients [34] found tumour
heterogeneity is associated with disease recurrence.
Limitations and strengths
The study has several strengths. First, we used data from
two well-characterised UK treatment centres with uniform
treatment protocols. Second, to minimise the risk of
heterogeneity in scanning parameters and quality over
time and between centres, scan quality parameters were
evaluated. Third, in-house written software was employed,
which allowed contouring in multiple planes, facilitating
accurate volume quantification.
The study has several limitations. First, with only 80 pa-
tients, it is a relatively small sample size. Second, to enrich
for events we used a case-control study design. This ap-
proach is biased in that it overestimates performance char-
acteristics [22] and hence we powered using a very
conservative α < 0.001. Third, we fell just short of our target
sample size. An improvement of 9% in the ROCAUC for
mrTV over mrT-size was statistically significant at p =
0.024, and might be clinically meaningful. A similar 9% was
noted with the IDI method, and while the NRI was poten-
tially promising at 34%, it had much uncertainty. Fourth, as
a retrospective study, there are potential biases and con-
founding. To mitigate against some of these, the assessors
were blinded. Finally, the study recognises that ‘drawing’
tumour volume on MR is currently imprecise. It is challen-
ging to differentiate peri-tumour oedema and fibrosis from
tumour tissue and pathological validation of TV measure-
ments was not possible. Indeed, tumour delineation is one
of the most uncertain aspects of RT planning and as such,
assessment of tumour volume for the purpose of prediction
is subject to the same issues [35–39]. This is reflected in
the moderate-good intra- and inter-observer concordance.
In a parallel set of data (unpublished), we found there is
modest intra- and inter-observer variability for T-size (ICC
for intra-observer variability: 0.86; ICCs for inter-observer
variability ranging from 0.73 to 0.82).
Clinical implications and future research
The findings from this study suggest that 3D MR-based
tumour volume quantification may enhance prediction of
LRF risk over current MR-based methods. We speculate
that TV better reflects tumour biology and could facilitate
risk stratification to improve the precision of personalised
treatment. The main limitation is that tumour ROI defin-
ition on MR is not currently routinely performed, and can
be time consuming. MR-based RT planning, currently in-
vestigated in tumours such as rectal adenocarcinoma [40],
may become routine in the future for SCCA, requiring
tumour delineation for treatment planning which can then
be reused as a prognostic factor. Techniques for auto-
mated contouring may also offer a time-sparing solution
in the future, once developed and validated. Our hypoth-
esis must now be evaluated – for example by, ‘piggy-back-
ing’ mrTV definition onto ongoing trials.
Tumour regression grading has been found to predict
for early local failure in SCCA [41]. Further work examin-
ing the role of measured tumour volume reduction follow-
ing CRT may provide more prognostic information;
however, differentiating tumour from fibrosis and oedema
following CRT is a significant challenge.
PET-CT is increasingly used in the pre-treatment as-
sessment of anal cancer and small studies demonstrate the
Table 2 Univariable and multivariable AUCs from ROCs for
outcome of loco-regional failure (N = 80)
Univariable Multivariablea
Variable AUC (95% CI) AUC
Gender 0.534 (0.427–0.642)
Age (years) 0.463 (0.333–0.592)
T-Size (cm) 0.731 (0.617–0.846) 0.738b
Tumour Volume (cm3) 0.817 (0.720–0.915) 0.801b
Nodal status 0.638 (0.531–0.744)
CI Confidence Interval
aThese are two variable models – the variable listed in the left-hand column
plus nodal status
b No 95% CIs are returnable in these post-estimations
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potential prognostic role of metabolic tumour volume
(MTV) [42–45]. Large scale exploration of the prognostic
role of MTV could be useful, and since PET-CT does not
necessarily detect areas of tumour necrosis [46], which are
unlikely to contain clonogenic cells, an important factor in
the probability of cure, examining the predictive role of
MTV relative to TV would be of interest.
Lastly, we acknowledge that looking at a single param-
eter to predict LRF is simplistic and it is more realistic
that a number of patient, biological, tumour and radio-
logical features each contribute to prognostic outcomes
in anal cancer [47], and are likely to be incorporated into
future risk-adapted treatment strategies. A multipara-
metric prognostic model incorporating all of these fea-
tures would be ideal, but investigating this issue is
outside of the remit of this preliminary study. Larger-
scale studies that facilitate this and are in progress. We
have, however, identified mrTV to be a potentially useful
prognostic tool, to be studied within such future models.
Conclusions
These preliminary results suggest that 3D MR-based
tumour volume quantification may improve prediction of
LRF in patients with SCCA following CRT over currently
employed measurements. Further work will be required to
refine ROI contouring, both in regards to facilitating a less
time consuming and more reproducible process, and to
explore the role of this tumour volume within multipara-
metric prognostic models for LRF in SCAA.
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